A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Recruiting
Observational Study
Familial Mediterranean Fever
Still Disease
Systemic Juvenile Idiopathic Arthritis
Adult-Onset Still Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 1 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 160 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
* Have data on clinical characteristics and treatments available for at least 3 …
Contacts
Novartis Pharmaceuticals
CONTACT